Does multivessel treatment during primary angioplasty improve clinical or economical outcomes compared to culprit-lesion-only treatment in patients with acute myocardial infarction?
A staged approach to multivessel treatment during primary angioplasty for AMI is preferred, as initial aggressive multivessel stenting offers no additional clinical or economic advantages.
Multivessel treatment during primary PTCA was safe in this controlled trial. However, when only the culprit lesion was initially treated, the need for subsequent clinically driven revascularization remained low and no clinical or economical advantages were obtainable with a more aggressive initial approach. In clinical practice, a staged approach to multivessel treatment during primary angioplasty avoids to treat unnecessarily non clinically relevant lesions.
Mario et al. (2004) studied this question.